Influence of particle size on regional lung deposition--what evidence is there?

The understanding of deposition of particles in the respiratory tract is of great value to risk assessment of inhalation toxicology and to improve efficiency in drug delivery of inhalation therapies. There are three main basic mechanisms of particle deposition based primarily on particle size: inertial impaction, sedimentation and diffusion. The regional deposition in the lungs can be evaluated in regards to the aerodynamic particle size, in which particle density plays a significant role. In this review paper, we first introduce the available imaging techniques to confirm regional deposition of particles in the human respiratory tract, such as planar scintigraphy, single photon emission computed tomography (SPECT) and positron emission tomography (PET). These technologies have widely advanced and consequently benefited the understanding of deposition pattern, although there is a lack of lung dosimetry techniques to evaluate the deposition of nanoparticles. Subsequently, we present a comprehensive review summarizing the evidence available in the literature that confirms the deposition of smaller particles in the smaller airways as opposed to the larger airways.

[1]  E. Daviskas,et al.  Deposition of aqueous aerosol of technetium-99m diethylene triamine penta-acetic acid generated and delivered by a novel system (AERx) in healthy subjects , 1999, European Journal of Nuclear Medicine.

[2]  R. Malcolmson,et al.  Dry powder formulations for pulmonary delivery , 1998 .

[3]  E. Daviskas,et al.  Lung deposition of mannitol powder aerosol in healthy subjects. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[4]  P. Jaques,et al.  Total Lung Deposition of Ultrafine Particles in Elderly Subjects During Controlled Breathing , 2005, Inhalation toxicology.

[5]  D. Tashkin,et al.  Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. , 2003, Clinical therapeutics.

[6]  N. Kenya Montreal Protocol Parties: Adjustments and Amendments to the Montreal Protocol on Substances that Deplete the Ozone Layer , 1991, International Legal Materials.

[7]  G. P. Martin,et al.  Particulate Interactions in Dry Powder Formulations for Inhalation , 2000 .

[8]  C. Leach,et al.  Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[9]  E. Daviskas,et al.  SPECT Imaging for Radioaerosol Deposition and Clearance Studies. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[10]  Pieter Zanen,et al.  The optimal particle size for parasympathicolytic aerosols in mild asthmatics , 1995 .

[11]  Gerhard Scheuch,et al.  Left-to-right asymmetry of aerosol deposition after shallow bolus inhalation depends on lung ventilation. , 2009, Journal of aerosol medicine and pulmonary drug delivery.

[12]  S. Newman,et al.  Scintigraphic assessment of therapeutic aerosols. , 1993, Critical reviews in therapeutic drug carrier systems.

[13]  Warren H. Finlay,et al.  Particle deposition in the respiratory tract , 2019, The Mechanics of Inhaled Pharmaceutical Aerosols.

[14]  B. Hammer,et al.  Magnetic Deposition of Aerosols Composed of Aggregated Superparamagnetic Nanoparticles , 2010, Pharmaceutical Research.

[15]  S. Newman,et al.  Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. , 2002, Respiratory medicine.

[16]  Jeffry D. Schroeter,et al.  Fundamental Effects of Particle Morphology on Lung Delivery: Predictions of Stokes' Law and the Particular Relevance to Dry Powder Inhaler Formulation and Development , 2002, Pharmaceutical Research.

[17]  M. Dolovich,et al.  Labiris NR, Dolovich MB. Pulmonary drug delivery: part II. the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications , 2004 .

[18]  V. Sollich,et al.  Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[19]  E. Daviskas,et al.  Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. , 2008, International journal of pharmaceutics.

[20]  H. Frijlink,et al.  Positron Emission Tomography Studies of Human Airways Using an Inhaled β-Adrenoceptor Antagonist, S-11 C-CGP 12388 , 2005 .

[21]  E. Daviskas,et al.  Changes in lung deposition of aerosols due to hygroscopic growth: a fast SPECT study. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[22]  A. Coates,et al.  Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: A pilot project , 2008, Pediatric pulmonology.

[24]  M. Newhouse,et al.  Factors that affect the efficacy of inhaled corticosteroids for infants and young children. , 2010, The Journal of allergy and clinical immunology.

[25]  Y. Cheng,et al.  Lung Deposition of Droplet Aerosols in Monkeys , 2008 .

[26]  J. Lammers,et al.  The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler , 1998, European Journal of Clinical Pharmacology.

[27]  Dongming Hwang,et al.  Three-dimensional simulations of airways within human lungs , 2007, Cell Biochemistry and Biophysics.

[28]  L. Borgström,et al.  Lung deposition of budesonide in asthmatics: a comparison of different formulations , 1998 .

[29]  G. Scheuch,et al.  Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. , 2004, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[30]  J. Lammers,et al.  Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. , 1996, Thorax.

[31]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[32]  O. Usmani,et al.  Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .

[33]  M. Dolovich,et al.  18F-fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery. , 2009, Proceedings of the American Thoracic Society.

[34]  Richard J Martin Therapeutic significance of distal airway inflammation in asthma. , 2002, The Journal of allergy and clinical immunology.

[35]  D. J. Alexander,et al.  Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) following whole-body exposure. , 2000, Regulatory toxicology and pharmacology : RTP.

[36]  S. Newman,et al.  Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. , 2003, Advanced drug delivery reviews.

[37]  Bhavna,et al.  Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[38]  C. Leach,et al.  Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. , 1998, The European respiratory journal.

[39]  A. James,et al.  The structure of large and small airways in nonfatal and fatal asthma. , 1993, The American review of respiratory disease.

[40]  A. Elaissari,et al.  Assessment methods of inhaled aerosols: technical aspects and applications , 2009, Expert opinion on drug delivery.

[41]  Dolovich Ma Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. , 2000 .

[42]  A Birchall,et al.  In vivo measurement of unattached radon progeny deposited in the human respiratory tract. , 2001, Radiation protection dosimetry.

[43]  C Kleinstreuer,et al.  Targeted drug-aerosol delivery in the human respiratory system. , 2008, Annual review of biomedical engineering.

[44]  M. Affrime,et al.  Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. , 2000, Clinical therapeutics.

[45]  M. Dolovich,et al.  Imaging drug delivery and drug responses in the lung. , 2004, Proceedings of the American Thoracic Society.

[46]  S. Farr The physico-chemical basis of radiolabelling metered dose inhalers with 99mTc. , 1996, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[47]  K. Ensing,et al.  Characterisation of β2-adrenoceptors, using the agonist []formoterol and positron emission tomography , 1998 .

[48]  Newman,et al.  Imaging techniques for assessing drug delivery in man. , 1999, Pharmaceutical science & technology today.

[49]  M. R. Bailey,et al.  EFFECT OF PARTICLE SIZE ON SLOW PARTICLE CLEARANCE FROM THE BRONCHIAL TREE , 2008, Experimental lung research.

[50]  H. Chrystyn Methods to identify drug deposition in the lungs following inhalation. , 2001, British journal of clinical pharmacology.

[51]  K. Amighi,et al.  Formulation strategy and use of excipients in pulmonary drug delivery. , 2010, International journal of pharmaceutics.

[52]  W. Hofmann,et al.  Aerosol Drug Delivery Optimization by Computational Methods for the Characterization of Total and Regional Deposition of Therapeutic Aerosols in the Respiratory System , 2007 .

[53]  Z. Lee,et al.  Regional distribution and kinetics of inhaled pharmaceuticals. , 2000, Current pharmaceutical design.

[54]  G. Scheuch,et al.  PULMONARY DEPOSITION OF MONODISPERSE AEROSOLS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE , 2003, Experimental lung research.

[55]  K. Amighi,et al.  Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. , 2008, International journal of pharmaceutics.

[56]  J. Fleming,et al.  A Technique for Simulating Radionuclide Images from the Aerosol Deposition Pattern in the Airway Tree , 1997 .

[57]  C. Robertson,et al.  Aerosol deposition in infants with cystic fibrosis , 1996, Pediatric pulmonology.

[58]  Richard B Thompson,et al.  MRI measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide nanoparticles. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[59]  Hak-Kim Chan,et al.  In vitro/in vivo comparisons in pulmonary drug delivery. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[60]  M. Dolovich,et al.  Synthesis and in vitro evaluation of 18F- and 19F-labeled insulin: a new radiotracer for PET-based molecular imaging studies. , 2006, Journal of medicinal chemistry.

[61]  J. Fleming,et al.  3D in silico modeling of the human respiratory system for inhaled drug delivery and imaging analysis. , 2007, Journal of pharmaceutical sciences.

[62]  J. Wildhaber,et al.  A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children. , 2004, Swiss medical weekly.

[63]  G. Rudolf,et al.  Intercomparison of Experimental Regional Aerosol Deposition Data , 1989 .

[64]  G. Hedenstierna,et al.  Deposition of Terbutaline in the Large or Small Airways: A Single-Center Pilot Study of Ventilation-Perfusion Distributions and Airway Tone , 2002 .

[65]  Z. Lee,et al.  Imaging studies of biodistribution and kinetics in drug development , 2003 .

[66]  A. Clark,et al.  A Comparison of the Pulmonary Bioavailability of Powder and Liquid Aerosol Formulations of Salmon Calcitonin , 2008, Pharmaceutical Research.

[67]  M. Apte,et al.  Unattached radon progeny as an experimental tool for dosimetry of nanoaerosols: Proposed method and research strategy , 2010, Inhalation toxicology.

[68]  David Price,et al.  Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. , 2010, Respiratory medicine.

[69]  Dongming Hwang,et al.  In silico modeling of asthma. , 2003, Advanced drug delivery reviews.

[70]  B. Shekunov,et al.  Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications , 2007, Pharmaceutical Research.

[71]  Albert H. L. Chow,et al.  Particle Engineering for Pulmonary Drug Delivery , 2007, Pharmaceutical Research.

[72]  I. Gonda,et al.  Targeting by deposition , 1992 .

[73]  G. Kim Prisk,et al.  Deposition of inhaled particles in the human lung is more peripheral in lunar than in normal gravity , 2008, European Journal of Applied Physiology.

[74]  W. Kreyling,et al.  Corrections in dose assessment of 99mTc radiolabeled aerosol particles targeted to central human airways using planar gamma camera imaging. , 2009, Journal of aerosol medicine and pulmonary drug delivery.

[75]  P Hagedoorn,et al.  Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. , 2002, International journal of pharmaceutics.

[76]  Ali A. Rostami,et al.  Computational Modeling of Aerosol Deposition in Respiratory Tract: A Review , 2009, Inhalation toxicology.

[77]  W. Koch,et al.  Particle deposition in the lung of the Göttingen minipig , 2010, Inhalation toxicology.

[78]  S. Cryan,et al.  In vivo animal models for drug delivery across the lung mucosal barrier. , 2007, Advanced drug delivery reviews.

[79]  Jolyon P Mitchell,et al.  Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[80]  W. Busse,et al.  Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. , 2000, The Journal of allergy and clinical immunology.

[81]  J. Wildhaber,et al.  Deposition of aerosols in infants and children. , 2004, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[82]  P. Iozzo,et al.  In vivo imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodine-124 labelled human insulin. , 2002, Nuclear medicine and biology.

[83]  J. Heyder,et al.  Intrapulmonary distribution of deposited particles. , 1999, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[84]  I. Wilding,et al.  Gamma scintigraphy in the evaluation of pharmaceutical dosage forms , 2004, European Journal of Nuclear Medicine.

[85]  R. Schlesinger,et al.  Comparative deposition of inhaled aerosols in experimental animals and humans: a review. , 1985, Journal of toxicology and environmental health.

[86]  Simon Cawthorne,et al.  Particle engineering techniques for inhaled biopharmaceuticals. , 2006, Advanced drug delivery reviews.

[87]  G. Smaldone,et al.  Effect of tubing deposition, breathing pattern, and temperature on aerosol mass distribution measured by cascade impactor. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[88]  James D. Crapo,et al.  Lower Respiratory Tract Structure of Laboratory Animals and Humans: Dosimetry Implications , 1993 .

[89]  Z. Lee,et al.  Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  Stefan Eberl,et al.  Aerosol deposition and clearance measurement: a novel technique using dynamic SPET , 2001, European Journal of Nuclear Medicine.

[91]  R. Condos,et al.  Lung deposition and respirable mass during wet nebulization. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[92]  M. L. Laucks,et al.  Aerosol Technology Properties, Behavior, and Measurement of Airborne Particles , 2000 .